Logotype for Novolog (Pharm-Up 1966) Ltd

Novolog (NVLG) Q1 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Novolog (Pharm-Up 1966) Ltd

Q1 2025 earnings summary

16 Jun, 2025

Executive summary

  • Revenue for Q1 2025 rose to ₪2,021.6 million, a 9.8% increase year-over-year, driven by logistics division growth and higher private market sales.

  • Net income for the quarter was ₪40.99 million, up from ₪13.23 million in Q1 2024.

  • Gross profit reached ₪180.8 million, with a gross margin of 8.9%, slightly down due to one-time SAP implementation costs.

  • Adjusted EBITDA for the quarter was ₪33.6 million, compared to ₪38.6 million in Q1 2024.

  • The company faced operational challenges from the SAP ERP rollout, impacting logistics and incurring one-time costs.

Financial highlights

  • Revenue: ₪2,021.6 million (Q1 2025), up from ₪1,840.8 million (Q1 2024).

  • Net income: ₪40.99 million (Q1 2025) vs. ₪13.23 million (Q1 2024).

  • Gross profit: ₪180.8 million (Q1 2025) vs. ₪169.2 million (Q1 2024).

  • Adjusted EBITDA: ₪33.6 million (Q1 2025) vs. ₪38.6 million (Q1 2024).

  • Operating cash flow: negative ₪14 million, compared to positive ₪158.5 million in Q1 2024.

Outlook and guidance

  • Management is implementing efficiency measures in logistics following SAP rollout issues.

  • No material negative impact identified from Israel's credit rating downgrade or new US tariffs as of report date.

  • The company is expanding logistics capacity and investing in digital health platforms.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more